Skip to main content

Pacira BioSciences to Participate in Fireside Chats at Three Upcoming Healthcare Conferences

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

BRISBANE, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in analyst-led fireside chats at the following three healthcare conferences:

  • 2026 RBC Capital Markets Global Healthcare Conference on Wednesday, May 20th at 8:30AM ET.
  • 2026 Jefferies Global Healthcare Conference on Wednesday, June 3rd at 9:55AM ET.
  • Goldman Sachs 47th Annual Global Healthcare Conference 2026 on Monday, June 8th at 1:20PM ET.

Live audio of the events can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.

About Pacira

Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera®º, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing a pipeline of clinical-stage assets for musculoskeletal pain and adjacencies, its most advanced product candidate, PCRX-201 (enekinragene inzadenovec), a novel locally administered gene therapy in Phase 2 clinical development for osteoarthritis of the knee. To learn more about Pacira, visit www.pacira.com.


Company Contact:
Pacira BioSciences, Inc.
Christian Pedetti
(973) 254-4387
Christian.pedetti@pacira.com

Primary Logo

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  270.12
+4.30 (1.62%)
AAPL  299.94
+5.13 (1.74%)
AMD  447.18
-1.11 (-0.25%)
BAC  50.12
-0.66 (-1.31%)
GOOG  399.57
+15.75 (4.10%)
META  618.10
+15.10 (2.50%)
MSFT  404.91
-2.86 (-0.70%)
NVDA  227.22
+6.44 (2.92%)
ORCL  189.62
+2.79 (1.49%)
TSLA  447.94
+14.49 (3.34%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.